Disclaimer

You are now leaving www.esmya.com. Links to other websites are provided as a resource to our visitors.

Gedeon Richter accepts no responsibility for the content of other websites.

Events

SEUD 2016 in Barcelona

2nd Congress of the Society of
Endometriosis and Uterine Disorders.

12-14 May 2016

COGI 2016 (Amsterdam)

cogi

COGI 2016 (Amsterdam)

The 24th World Congress on Controversies in Obstetrics, Gynecology & Infertility. November 10-13 2016.

Information to be announced closer to the date

ESGE 2016 (Brussels)

esge

ESGE 2016 (Brussels)

25th Annual Congress of European Society for Gynaecological Endoscopy.

Information to be announced closer to the date

ISGE 2016 (Florence)

isge

ISGE 2016 (Florence)

17th Congress of International Society of Gynecological Endocrinology. 2-5 March 2016.

Information to be announced closer to the date

SEUD 2016 (Barcelona)

seud

SEUD 2016 (Barcelona)

2nd Congress of the Society of Endometriosis and Uterine Disorders. 12-14 May 2016.

Information to be announced closer to the date

ESG 2015 (Prague)

ESG-2015Prague

ESG 2015 (Prague)

Long term management of uterine fibroids with Ulipristal Acetate
11th Congress of European Society of Gynecology. 21-24 October 2015.

Chairperson/s:

  • Genazzani Andrea R. (IT), Kucera Eduard (CZ)
  • Chabbert-Buffet Nathalie (FR) MoA and application of the SPRMs
  • Matule Dace (LV) PEARL IV Study: Latest results from the long term intermittent use of Ulipristal Acetate
  • Arriagada Pablo (CH) PEARL Extension II Study: Cumulative experience after 8 treatment courses with Ulipristal Acetate
  • Deans Anne (GB) Long Term management of UF with Ulipristal Acetate: Practical guidance for clinicians

ESGE 2015 (Budapest)

esge_budapest

ESGE 2015 (Budapest)

Role of Medical Treatment and Surgery for the Long-term Management of Fibroids
24th Annual Congress of European Society for Gynaecological Endoscopy. October 7th – 10th, 2015

Agenda

ESGE 2015 (Budapest)

Selective Progesterone Receptor Modulators (SPRMs) are a new class of compounds with great potential in the treatment of Uterine Fibroids. The presentations in this scientific session discussed the potential use of Esmya® in the long term management of symptomatic Uterine Fibroids as well as its use in pre-operative setting.

EBCOG 2014 Glasgow

EBCOG2014


Esmya®: the PEARL studies and clinical experience two years on 23rd European Congress of Obstetrics and Gynaecology. May 8th, 2014

Selective Progesterone Receptor Modulators and their role in women’s health :

  • Dr. Tahir Mahmood, Consultant Obstetrician & Gynaecologist, Victoria Hospital, Kirkcaldy, Fife, UK;
    President Elect, European Board & College of Obstetrics & Gynaecology (EBCOG) 2011-2014
    The ongoing development of Esmya®, PEARL III and the future
  • Professor Jacques Donnez, Professor Emeritus, Université Catholique de Louvain, Brussels, Belgium
    Progesterone Receptor Modulators and their effects on the endometrium – real world experience
  • Professor Alistair Williams, Reader in Pathology and Honorary Consultant in Pathology, Department of Pathology, University of Edinburgh, UK
    Esmya®: practical experience in the clinical setting
  • Miss Jennifer Parratt, Consultant in Obstetrics and Gynaecology, Chesterfield Royal Hospital, Chesterfield, UK
1jan12:00 am- 12:00 amEBCOG 2014 GlasgowEsmya: the PEARL studies and clinical experience two years on 23rd European Congress of Obstetrics and Gynaecology.

ESG 2013 Brussels

logo_SEGOPENING SYMPOSIUM – LONG-TERM MEDICAL MANAGEMENT OF FIBROIDS WITH SPRMs

Selective Progesterone Receptor Modulators (SPRM) are a new class of compounds that are able to inhibits or stimulate molecular factors called Progesterone Response Elements, by recruiting transcriptional co-activators or co-repressors depending on the target tissue. The double action allows an accurate management of uterine fibroids and there are promising data even in endometriosis.

The presentations in this symposium discussed the clinical data of Ulipristal Acetate for repeated courses in the long term medical treatment, and highlighted relevant points coming from PEARL III & Extension clinical trials.

The program 
18sep - 21sep 1812:00 amsep 21ESG 2013 BrusselsOPENING SYMPOSIUM – LONG-TERM MEDICAL MANAGEMENT OF FIBROIDS WITH SPRMs : Opening Symposium

FIGO 2012 Roma

13a40be2f60

SATELLITE SYMPOSIUM AT THE 20TH FIGO WORLD CONGRESS 2012 IN ROME

Monday, 8th October 2012, 12h30 – 13h30
Sala Raffaella Alibrandi (Room F & G), Hall 10, Fiera di Roma

From developpment to clinical use: an overview of SPRMs

  • Professor Hilary OD Critchley
Insights on MoA: SPRMs & Fibroid Shrinkage

  • Dr. Ernest Lournaye
Detailed analysis of Menstrual Bleeding and Review of Safety after treatment of Uterine Fibroids with Ulipristal Acetate treatment: PEARL III Clinical studies

  • Pr. Jacques Donnez
A Randomised Placebo-controlled Trial Assessing the Putative Benefit of a Progestin Course following Ulipristal Acetate treatment: PEARL III Clinical study

  • Pr. Bart CJM. Fauser
Interactive Question & Answer Session

  • Pr. David H. Barlow (Chair)
  • Pr. Andrea R. Genazzani (Co-Chair)
7oct - 12oct 712:00 amoct 12FIGO 2012 RomaUlipristal Acetate: New SPRM Therapeutics for Uterine Fibroids

ESG 2011 Copenhagen

logo_SEG

New Medical Management of Uterine Fibroids: The Mounting Evidence with Ulipristal Acetate Clinical Data.

 

 

Agenda

Carstensen (Auditorium 1) | TIVOLI CONGRESS CENTER
2-4 Arni Magnussons Gade, 1577 Copenhagen, Denmark
Friday, 9th September, 2011 | 14:00 – 15:30 pm

  • 14:00 – 14:15 | Pharmacology & MoA of SPRM Therapy / Prof Philippe Bouchard, France
  • 14:15 – 14:30 | Clinical Development of SPRMs: Insights from PEARL / Dr Ernest Loumaye, Switzerland
  • 14:30 – 15:00 | The Mounting Evidence with PEARL: Ulipristal Acetate Clinical Data / Prof Jacques Donnez, Belgium
  • 15:00 – 15:15 | Panel Discussion: The Potential Impact of Ulipristal Acetate on the current Clinical Management of Uterine Fibroids / Prof David H Barlow (Co-chair), UK
  • 15:15 – 15:30 | Question-and-Answer Session & Closing Remarks / Prof Sven O Skouby (Chair), Denmark
1jan12:00 am- 12:00 amESG 2011 CopenhagenNew Medical Management of Uterine Fibroids: The Mounting Evidence with Ulipristal Acetate Clinical Data.

EBCOG 2010 Antwerp

2011_7_4112

SPRMs: Towards a New Medical Treatment for Uterine Fibroids

Selective Progesterone Receptor Modulators (SPRM) are a new class of compounds that offer a promising new treatment option for uterine fibroids. The presentations in this symposium discussed the pharmacology and mode of action of SPRM, the clinical development of SPRM and the recent clinical data of ulipristal acetate from the PEARL studies.
Our faculty of leading experts hosted a discussion on the role of SPRMs in the medical treatment of uterine fibroids according to ulipristal acetate clinical data and highlighted points relevant to clinical practice.

Agenda

Venue:
Darwin Hall, Flanders Concert and Congress Centre (F.C.C.C.) Koningin Astridplein 23-26, 2018 Antwerp, Belgium Thursday, 6th May 2010, 14:00 – 15:15
Chair: Prof. Pedro N. Barri, Insituto Universitario Dexeus, Spain

The rationale behind SPRM therapy(Speaker: Prof. David Barlow, The University of Glasgow, UK)
Recent experience of SPRM therapy: Understanding its impact on the endometrium(Speaker: Dr. Alistair RW Williams, The University of Edinburgh, UK)
Clinical benefits of SPRM therapy: New insights from Phase II data(Speaker: Prof. Jacques Donnez, Université Catholique de Louvain, Belgium)
Final Thoughts: Clinical implications, considerations for surgery, and what remains to be discovered(Speaker: Prof. Pedro N. Barri, Insituto Universitario Dexeus, Spain)
Questions & Answers
1jan12:00 am- 12:00 amEBCOG 2010 AntwerpSPRMs: Towards a New Medical Treatment for Uterine Fibroids

ESG 2009 Roma

logo_SEG

Satellite Symposium at the 8th Congress of the European Society of Gynecology

Selective progesterone receptor modulators (SPRM) are a new class of compounds with great potential in the treatment of uterine fibroids. The presentations in this symposium discussed the pharmacology of SPRM and their effect on the endometrium, before moving on to review recent clinical outcomes with SPRM and identifying how they might be used in the management of uterine fibroids.

Agenda

Hall Pio X, MONUMENTAL COMPLEX OF SANTO SPIRITO IN SAXIA, Borgo Santo Spirito 1, 00193 Rome, Italy
Friday, 11th September 2009 | 09:10 – 10:40

Co-Chairs:
Bart Fauser, The Netherlands
Andrea Genazzani, Italy

  • 09:10 – 09:15 | Introduction: Why clinicians must re-evaluate what they can offer symptomatic patients | Bart Fauser, The Netherlands
  • 09:15 – 09:35 | SPRM class: Mode of action, and do SPRMs differ from each other? | Philippe Bouchard, France
  • 09:35 – 09:55 | Features of selective progesterone receptor modulator (SPRM) associated endometrial changes | George Mutter, USA
  • 09:55 – 10:15 | The proof of evidence: PGL4001 (ulipristal acetate) Phase II clinical data| Lynnette Nieman, USA
  • 10:15 – 10:35 | SPRMs in clinical practice: Are there any implications for surgery? | Jacques Donnez, Belgium
  • 10:35 – 10:40 | Question and answer session | Andrea Genazzani, Italy
10sep - 11sep 1012:00 amsep 11ESG 2009 RomaSPRM: Towards a new paradigm in the treatment of uterine fibroids
7fc16655c1
/wp-admin/options-general.php?page=emc2-popup-disclaimer%2Femc2pdc-admin.php
65dc6cecd1
2090
1
Accept
Decline
http://fibroidsconnect.com/
1

For Healthcare Professionals only

This information contained in this website was specifically created for healthcare professionals. Please tick here to confirm that you are a licensed healthcare professional.
Registration conditions of ESMYA® could differ in each country, please refer to your local regulations for more information.

Accept Decline